FDA panel recommends peginesatide for patients on dialysis

12/7/2011 | MedPage Today (free registration)

An FDA panel recommended the synthetic erythropoiesis-stimulating agent, or ESA, peginesatide as an alternative treatment for anemia in patients with chronic kidney disease undergoing dialysis. The drug, made by Affymax, works comparably to standard ESAs in increasing hemoglobin level and limiting blood transfusions in patients on dialysis, the panel said. The drug, if approved, will not be used in patients not on dialysis or patients with cancer.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX